FDA Issues Draft Guidance on Responding to Form 483 Observations

In March 2026, the U.S. Food and Drug Administration (FDA or the Agency) issued the draft guidance for industry, Responding to FDA Form 483 Observations at the Conclusion of a Drug CGMP Inspection.¹ The draft guidance provides FDA’s current approach on how human and animal drug manufacturers should structure and submit written responses to FDA Form 483 observations issued at the close of an FDA inspection that evaluated conformity with current good manufacturing practices (cGMPs).² It also outlines FDA’s expectations for the organization, content, and timing of written responses, as well as recommended approaches for investigations, corrective actions, and communications with the Agency. Comments on the draft guidance are due by May 8, 2026.³

Although the guidance implicitly communicates that responding to an FDA Form 483 is voluntary (which, technically, it is), establishments should consider a response to be mandatory. The Form 483 response is the establishment’s opportunity to respond to what FDA observed in the inspection, to outline plans for remediation and corrective action, and sets the tone for further engagement with FDA and how seriously the establishment takes the observations received. Indeed, FDA emphasizes that a written 483 response “may be the primary or a key component in FDA’s review when evaluating whether subsequent Agency action is warranted.”⁴

Below, we provide an overview of the draft guidance, beginning with a brief background on FDA Form 483 observations and the role of written responses, followed by a discussion of FDA’s recommendations regarding the structure and timing of responses, investigation and CAPA expectations, and strategies for addressing inspectional observations.

Background

FDA investigators will issue a Form 483 at the conclusion of an FDA inspection if they observe conditions that, in their judgment, may constitute violations of the Federal Food, Drug, and Cosmetic Act or FDA regulations (e.g., the cGMP requirements in 21 CFR Parts 210 and 211). A Form 483 lists inspectional observations but does not represent FDA’s final conclusions regarding compliance.

FDA has long encouraged companies to respond promptly and thoroughly to such observations. FDA recommends submitting a written response within 15 business days of the issuance of the Form 483. Responses received after this timeframe will be considered untimely and the agency may not consider them when it classifies the inspection and determines whether to pursue compliance action, such as a warning letter and/or import alert.

Recommended Structure and Content of a Response

The draft guidance provides detailed recommendations for the format and content of a written response. FDA encourages submissions that are clear, organized, and comprehensive. Per FDA, responses should generally include:

• Identification of the establishment submitting the response, including the facility name, address, and FDA Establishment Identifier
• A copy of the issued Form 483
• Identification of the response preparer and the signatory (who should be a member of executive management with authority to allocate resources and implement corrective actions)
• Any authorization letters if the company retained consultants or outside counsel⁵
• Any associated global investigation plans and reports
• An executive summary of all remediation activities with a detailed description of each observation and remediation activities, including:
  • A patient- and product-focused risk assessment of observations, with an assessment of inventory and distributed drugs within expiry and possible effects on safety, identity, strength, quality, and purity of potentially affected drugs
  • A detailed investigation report with scope, summary, list of associated drugs and lot numbers, identified root causes and related systemic issues, corrective and preventative action (CAPA) plan, a summary of completed actions, including interim actions, and a planned effectiveness evaluation
  • Signed attachments related to the associated observation, including documents, pictures, video, diagrams, or data

Notably, the draft guidance recommends that companies may include an executive summary table to organize remediation information. FDA indicates that this type of summary can facilitate its review by providing a concise overview of corrective actions and implementation timelines.

Investigations and Root Cause Analysis

The guidance emphasizes that responses should demonstrate that the establishment has thoroughly evaluated the observations and their underlying causes. FDA recommends that manufacturers develop a comprehensive investigation plan, including a scientifically justified scope and methodology. Investigations should assess whether the deficiencies identified affect other drugs, processes, or facilities and should identify any systemic issues that may require broader remediation. The response should include details regarding the investigation, including: scope and methodology; root cause analysis; identification of affected products or batches; and actions taken to prevent recurrence. FDA also notes that companies may need to expand the scope of investigations if additional information indicates that similar issues may exist elsewhere in the manufacturing process.

CAPA Plans and Effectiveness Checks

The draft guidance emphasizes the importance of developing a CAPA plan during, or immediately after, the close of an inspection to address issues underlying the observations. CAPA plans should include: corrective actions addressing root causes identified during the investigation; preventative actions designed to prevent recurrence; implementation timelines and deliverables; and effectiveness evaluations to verify that the corrective measures successfully resolve the issue. FDA recommends that effectiveness evaluations go beyond routine testing and demonstrate that the underlying problem has been fully addressed.

Interim Reporting and Ongoing Communication

When corrective actions cannot be completed within the initial response period, FDA encourages companies to provide interim updates and establish a communication plan for all ongoing remediation activities. This plan should include milestone deliverables and follow-up reports describing progress on remediation activities and the status of commitments made in the initial response, as well as what information would be included in these reports.

Addressing Scientific or Technical Disagreements

The draft guidance also acknowledges that companies may disagree with certain inspectional observations. In such cases, FDA recommends addressing the disagreement with the FDA representative during the inspection. In the event that a disagreement is not resolved before FDA issues a Form 483, companies should describe the contested facts in the Form 483 response, and provide scientific data or other supporting evidence explaining the company’s position. The response should reference applicable statutes, regulations, or guidance to support the company’s interpretation.

Key Takeaways

Through the draft guidance, FDA is communicating more explicit expectations about the substance and quality of a Form 483 response. Establishments may be accustomed to performing some of the recommended activities and providing some of the recommended information, as a best practice. Now, FDA is formally recommending elements that comprise a more uniform and extensive response to a Form 483, perhaps to globally elevate the quality and comprehensiveness of responses. Although the guidance does not create new legal requirements, manufacturers should review FDA’s guidance and consider whether their firm’s approach to Form 483 responses is aligned with FDA’s, and consider these recommendations when strategizing the scope of a Form 483 response and associated CAPAs.

For more information or to discuss FDA’s recommendations, please reach out to the Arnold & Porter authors. 

© Arnold & Porter Kaye Scholer LLP 2026 All Rights Reserved. This Advisory is intended to be a general summary of the law and does not constitute legal advice. You should consult with counsel to determine applicable legal requirements in a specific fact situation.